Company Description
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.
It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments.
The company is headquartered in Toronto, Canada.
Contact Details
Address: 100 King Street West, Suite 5600 Toronto, ON M5X 1C9 Canada | |
| Phone | 908 764 8385 |
| Website | helus.com |
Stock Details
| Ticker Symbol | HELP |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001833141 |
| CUSIP Number | 23256X407 |
| ISIN Number | CA23256X4075 |
Key Executives
| Name | Position |
|---|---|
| Michael I. Halstead J.D. | Chief Executive Officer |
| Eric So L.L.B. | Co-Founder, President and Executive Chairman |
| Paul Glavine | Co-Founder, Chief Growth Officer and Director |
| Greg Cavers | Chief Financial Officer |
| Aaron Bartlone | Chief Operating Officer |
| Dr. Amir Inamdar FFPM, MBBS | Chief Medical Officer |
| John Kanakis | Co-Founder |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Lori Challenger | Chief Compliance, Ethics and Administrative Officer |
| Gabriel Fahel | Chief Legal Officer and Corporate Secretary |